Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells

Thrombosis and Haemostasis

Volumn 99, Issue 1, 2008, Pages 133-141

  Nadir, Yona ^a,b   Brenner, Benjamin ^b   Gingis Velitski, Sveta ^a   Levy Adam, Flonia ^a   Ilan, Neta ^a   Zcharia, Eyal ^c   Nadir, Erez ^d   Vlodavsky, Israel ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d HILLEL YAFFE MEDICAL CENTER   (Israel)

Author keywords

Coagulation; Endothelial cells; Heparanase; TFPI; Tumor

Indexed keywords

HEPARAN SULFATE; HEPARANASE; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; CANCER CELL CULTURE; CELL SURFACE; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME REGULATION; EXTRACELLULAR SPACE; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; TRANSGENIC MOUSE; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

EID: 38349148914     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1608919     Document Type: Article

References (35)

1. Parish CR, Freeman C, Hulett MD, Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 2001; 1471: M99-108.
2. Vlodavsky I, Abboud-Jarrous G, Elkin M, et al. The impact of heparanese and heparin on cancer metastasis and angiogenesis. Pathophysiol Haemost Thromb 2006; 35: 116-127.
3. Bar-Sela G, Kaplan-Cohen V, Ilan N, et al. Heparanase expression in nasopharyngeal carcinoma inversely correlates with patient survival. Histopathology 2006; 49: 188-193.
4. Koliopanos A, Friess H, Kleeff J, et al. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res 2001; 61: 4655-4659.
5. Rohloff J, Zinke J, Schoppmeyer K, et al. Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinorna. By J Cancer 2002; 86: 1270-1275.
6. Gohji K, Hirano H, Okamoto M, et al. Expression of three extracellular matrix degradative enzymes in bladder cancer. Int J Cancer 2001; 95: 295-301.
7. Takaoka M, Naomoto Y, Ohkawa T, et al. Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab Invest 2003; 83: 613-622.
8. Tang W, Nakamura Y, Tsujimoto M, et al. Heparanase: a key enzyme in invasion and metastasis of gastric carcinoma. Mod Pathol 2002; 15: 593-598.
9. Shinyo Y, Kodama J, Hongo A, et al. Heparanase expression is an independent prognostic factor in patients with invasive cervical cancer. Ann Oncol 2003; 14: 1505-1510.
10. Sato T, Yamaguchi A, Goi T, et al. Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis. J Surg Oncol 2004; 87: 174-181.
11. Gingis-Velitski S, Zetser A, Flugelman MY, et al. Heparanase Induces Endothelial Cell Migration via Protein Kinase B/Akt Activation. J Biol Chem 2004; 279: 23536-23541.
12. Zetser A, Bashenko Y, Edovitsky E, et al. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 2006; 66: 1455-1463.
13. Elkin M, Ilan N, Ishai-Michaeli R, et al. Heparanase as mediator of angiogenesis: mode of action. Faseb J 2001; 15: 1661-1663.
14. Nadir Y, Brenner B, Zetser A, et al. Heparanase induces tissue factor expression in vascular endothelial and cancer cells. J Thromb Haemost 2006; 4: 2443-2451.
15. Gingis-Velitski S, Zetser A, Kaplan V, et al. Heparanase Uptake Is Mediated by Cell Membrane Heparan Sulfate Proteoglycans. J Biol Chem 2004; 279: 44084-44092.
16. Zetser A, Bashenko Y, Miao H-Q, et al. Heparanase Affects Adhesive and Tumorigenic Potential of Human Glioma Cells. Cancer Res 2003; 63: 7733-7741.
17. Zetser A, Levy-Adam F, Kaplan V, et al. Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 2004; 117: 2249-2258.
18. Hulett MD, Hornby JR, Ohms SJ, et al. Identification of active-site residues of the pro-metastatic endoglycosidase heparanase. Biochemistry 2000; 39: 15659-15667.
19. Levy-Adam F, Abboud-Jarrous G, Guerrini M, et al. Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J Biol Chem 2005; 280: 20457-20466.
20. Nardella C, Lahm A, Pallaoro M, et al. Mechanism of activation of human heparanase investigated by protein engineering. Biochemistry 2004; 43: 1862-1873.
21. Zcharia E, Metzger S, Chajek-ShaulL T, et al. Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J 2004; 18: 252-263.
22. Ho G, Broze GJ Jr, Schwartz AL. Role of heparan sulfate proteoglycans in the uptake and degradation of tissue factor pathway inhibitor-coagulation factor Xa complexes. J Biol Chem 1997; 16838-16844.
23. Fuki II, Iozzo RV, Williams KJ. Perlecan heparan sulfate proteoglycan. A novel receptor that mediates a distinct pathway for ligand catabolism. J Biol Chem 2000; 275: 25742-50.
24. Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol 2006; 208: 327-339.
25. Iversen N, Lindahl AK, Abildgaard U. Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Br J Haematol 1998, 102: 889-895.
26. Gerlach R, Scheuer T, Bohm M, et al. Increased levels of plasma tissue factor pathway inhibitor in patients with glioblastoma and intracerebral metastases. Neurol Res 2003; 25: 335-338.
27. Shafat I, Zcharia E, Nisman B, et al. An ELISA method for the detection and quantification of human heparanase. Biochem Biophys Res Commun 2006; 341: 958-963.
28. Vlodavsky I, Eldor A, Haimovitz-Friedman A, et al. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 1992; 12: 112-127.
29. Haim N, Lanir N, Hoffman R, et al. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med 2001; 110: 91-96.
30. Hoke M, Kyrle PA, Minar E, et al. Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism. Thromb Haemost 2005; 94: 787-790.
31. Sarig G, Blumenfeld Z, Leiba R, et al. Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss. Thromb Haemost 2005; 94: 980-985.
32. Mousa SA, Linhardt R, Francis JL, et al. A. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb Haemost 2006; 96: 816-21.
33. Hostettler N, Naggi A, Torri G, et al. P-selectin-and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J 2007; 21: 3562-3572.
34. Liu T, Scallan CD, Broze GJ Jr, et al. Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP). Thromb Haemost 2006; 95: 68-76.
35. Naggi A, Casu B, Perez M, et al. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem 2005; 280: 12103-12113.